Welcome to the Investor Relations section of the IXICO website
IXICO sells clinical data management and analysis products and services. Our technologies seek to improve diagnosis, assess progression and measure treatment outcomes of neuro-degenerative disorders including Huntington's disease, Multiple Sclerosis, Alzheimer's disease and other causes of dementia. We have commercial relationships with 9 out of the top 15 global pharmaceutical companies providing clinical trial services and are building on this core business as a digital healthcare technology provider for the diagnosis and management of dementia in clinical practice. Please see IXICO announces launch of dementia care digital platform with The NHSA Network for more details.
Our digital technologies are used in
In October 2013, IXICO became a public company by listing on AIM via a reverse takeover of Phytopharm Plc which enabled IXICO to accelerate its investments in new product development.
We recognise the importance of providing clear and timely information to our existing and potential shareholders and hope that you will find our website interesting.
Derek Hill recently caught up with 'Proactive Investors' to discuss the company's full year results and new partnerships. See full segment below.
"We're using technology that we have for many years been applying to support pharmaceutical companies developing drugs. We're now using that to help make those drugs safer when used with patients in the clinic once they're marketed'esults and new partnerships."
- Derek Hill, CEO IXICO
If you require further information please email us at email@example.com.
Note: IXICO is subject to the UK City Code on Takeover and Mergers; this site is provided for investors and is AIM Rule 26 compliant.
Share price and news information on this site is updated dynamically from external data feeds.